Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Casma Therapeutics has announced the development of CSM-101, a promising oral treatment designed to slow or stop the progression of Parkinson’s disease and Gaucher disease by improving the way cells clean out waste. How It Works: Restoring the Cell’s Recycling System CSM-101 is the first treatment of its kind to activate TRPML1, a protein that helps regulate lysosomes—the part of the cell responsible for breaking down and recycling waste. In Parkinson’s, waste builds up due to problems in this system, which can damage cells and accelerate disease progression. A Focus on Genetic Forms of Parkinson’s This therapy is especially relevant for people with GBA1 mutations, which impair an enzyme called GCase. These mutations significantly increase the risk of developing Parkinson’s, often with earlier onset and faster progression. By restoring lysosome function, CSM-101 may help reduce toxic protein buildup (like alpha-synuclein) that contributes to the disease’s motor symptoms. Backed by Preclinical Evidence and Support Early lab studies show that CSM-101 reaches the brain and spinal cord, lowers toxic levels of proteins and fats, reduces inflammation, and protects nerve cells. The therapy was also found to be safe and well tolerated in animal models. Development is supported by a $370,000 grant from the Michael J. Fox Foundation, and Casma plans to submit a request to begin human trials. Looking Ahead “By addressing a core issue in cell health—lysosomal dysfunction—we hope CSM-101 can offer real change for people living with Parkinson’s,” said Casma’s team.